RU2016115523A3 - - Google Patents

Download PDF

Info

Publication number
RU2016115523A3
RU2016115523A3 RU2016115523A RU2016115523A RU2016115523A3 RU 2016115523 A3 RU2016115523 A3 RU 2016115523A3 RU 2016115523 A RU2016115523 A RU 2016115523A RU 2016115523 A RU2016115523 A RU 2016115523A RU 2016115523 A3 RU2016115523 A3 RU 2016115523A3
Authority
RU
Russia
Application number
RU2016115523A
Other languages
Russian (ru)
Other versions
RU2681939C2 (ru
RU2016115523A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016115523A publication Critical patent/RU2016115523A/ru
Publication of RU2016115523A3 publication Critical patent/RU2016115523A3/ru
Application granted granted Critical
Publication of RU2681939C2 publication Critical patent/RU2681939C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0201Oxygen-containing compounds
    • B01J31/0209Esters of carboxylic or carbonic acids
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235Nitrogen containing compounds
    • B01J31/0237Amines
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235Nitrogen containing compounds
    • B01J31/0244Nitrogen containing compounds with nitrogen contained as ring member in aromatic compounds or moieties, e.g. pyridine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00Separation of optically-active compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2016115523A 2013-10-29 2014-10-29 Путь синтезирования 2'-дезокси-2'2'-дифтортетрагидроуридинов RU2681939C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361896703P 2013-10-29 2013-10-29
US61/896,703 2013-10-29
PCT/US2014/062874 WO2015066162A1 (en) 2013-10-29 2014-10-29 Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines

Publications (3)

Publication Number Publication Date
RU2016115523A RU2016115523A (ru) 2017-12-04
RU2016115523A3 true RU2016115523A3 (https=) 2018-06-05
RU2681939C2 RU2681939C2 (ru) 2019-03-14

Family

ID=51982743

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016115523A RU2681939C2 (ru) 2013-10-29 2014-10-29 Путь синтезирования 2'-дезокси-2'2'-дифтортетрагидроуридинов

Country Status (19)

Country Link
US (3) US9834576B2 (https=)
EP (1) EP3063164B1 (https=)
JP (1) JP6427567B2 (https=)
KR (1) KR102272773B1 (https=)
CN (1) CN105683209B (https=)
AU (1) AU2014342402B2 (https=)
BR (1) BR112016008855B1 (https=)
CA (1) CA2926734C (https=)
ES (1) ES2712877T3 (https=)
IL (1) IL244849B (https=)
MX (1) MX363205B (https=)
MY (1) MY176465A (https=)
NZ (1) NZ718607A (https=)
PH (1) PH12016500683B1 (https=)
RU (1) RU2681939C2 (https=)
SA (1) SA516371019B1 (https=)
SG (1) SG11201602614XA (https=)
WO (1) WO2015066162A1 (https=)
ZA (1) ZA201602315B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014342402B2 (en) 2013-10-29 2018-11-01 Taiho Pharmaceutical Co., Ltd Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines
US11224610B2 (en) 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
AU2020363412B2 (en) * 2019-10-08 2026-03-12 Taiho Pharmaceutical Co., Ltd. 2'-deoxy-2',2'-difluorotetrahydrouridines with high purity and methods of making the same
US12239653B2 (en) 2020-02-25 2025-03-04 Taiho Pharmaceutical Co., Ltd. Combination decitabine and cedazuridine solid oral dosage forms
AU2021311722A1 (en) 2020-07-24 2023-02-02 Elanco Us Inc. Process for making an isoxazoline compound and intermediate thereof
CN113402573B (zh) * 2020-07-31 2023-06-20 集美大学 一种鞣质类化合物及其提取方法和应用
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations
US20240279266A1 (en) * 2021-05-29 2024-08-22 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
TWI821074B (zh) * 2021-12-25 2023-11-01 台灣神隆股份有限公司 製備希達路里定(cedazuridine)的方法
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
FR2682112B1 (fr) 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
KR19990076695A (ko) 1995-12-22 1999-10-15 리차드 알. 이킨 시티딘 데아미나제 혹은 데옥시시티딘 데아미나제의 과발현과연관된 질병들을 치료하기 위한 활성제_및 방법
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
DE60144573D1 (de) 2000-11-29 2011-06-16 Mitsui Chemicals Inc Verfahren und Zwischenprodukte bei der Synthese von L-Thymidin
FI112640B (fi) 2000-12-22 2003-12-31 Kone Corp Hissin turvalaite
EP2043653B1 (en) * 2006-06-21 2013-12-25 Eli Lilly And Company Crystalline forms of gemcitabine amide prodrug, compositions and use thereof
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
AU2014342402B2 (en) 2013-10-29 2018-11-01 Taiho Pharmaceutical Co., Ltd Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines

Also Published As

Publication number Publication date
JP2017500281A (ja) 2017-01-05
AU2014342402B2 (en) 2018-11-01
NZ718607A (en) 2019-10-25
SG11201602614XA (en) 2016-05-30
CN105683209A (zh) 2016-06-15
US11028119B2 (en) 2021-06-08
PH12016500683B1 (en) 2020-02-14
ES2712877T3 (es) 2019-05-16
BR112016008855A2 (https=) 2017-08-01
KR20160083021A (ko) 2016-07-11
BR112016008855B1 (pt) 2023-01-17
RU2681939C2 (ru) 2019-03-14
IL244849A0 (en) 2016-05-31
CA2926734C (en) 2022-03-15
RU2016115523A (ru) 2017-12-04
EP3063164A1 (en) 2016-09-07
CN105683209B (zh) 2019-03-08
MY176465A (en) 2020-08-11
SA516371019B1 (ar) 2018-01-23
JP6427567B2 (ja) 2018-11-21
MX2016005596A (es) 2016-12-09
HK1223627A1 (en) 2017-08-04
IL244849B (en) 2019-10-31
KR102272773B1 (ko) 2021-07-02
US9834576B2 (en) 2017-12-05
US20200123189A1 (en) 2020-04-23
PH12016500683A1 (en) 2016-05-30
US20180072768A1 (en) 2018-03-15
US10526362B2 (en) 2020-01-07
ZA201602315B (en) 2019-07-31
WO2015066162A1 (en) 2015-05-07
CA2926734A1 (en) 2015-05-07
MX363205B (es) 2019-03-13
EP3063164B1 (en) 2018-12-05
AU2014342402A1 (en) 2016-04-21
US20160237107A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
AP2016009275A0 (https=)
BR112015007533A2 (https=)
BR102016010778A2 (https=)
BR112014017733A2 (https=)
BR112014018502A2 (https=)
BR112014017739A2 (https=)
BR112014019326A2 (https=)
BR112014018516A2 (https=)
BR112014018480A2 (https=)
BR112014017855A2 (https=)
BR112014020341A2 (https=)
BR112014017765A2 (https=)
BR112014017669A2 (https=)
BR112014021878A2 (https=)
BR112014019204A2 (https=)
BR112014018468A2 (https=)
BR112014017901A2 (https=)
BR112014018207A2 (https=)
BR112015015948A2 (https=)
BR112014017722A2 (https=)
BR112014017794A2 (https=)
BR112014017653A2 (https=)
BR112014018578A2 (https=)
BR112014018483A2 (https=)
RU2016115523A3 (https=)